{"result": "(\"entity\"<|>MADRID<|>GEO<|>Madrid is the capital city of Spain, where both the Hospital Clínico Universitario San Carlos and Centro de Salud Lucero are located.)\n##\n(\"entity\"<|>DIABETES<|>EVENT<|>Diabetes is a chronic health condition that is often associated with obesity and requires medical management.)\n##\n(\"entity\"<|>HYPERTENSION<|>EVENT<|>Hypertension is a medical condition characterized by high blood pressure, commonly associated with obesity and other health issues.)\n##\n(\"entity\"<|>DYSPLIPIDEMIA<|>EVENT<|>Dyslipidemia refers to abnormal levels of lipids in the blood, which can be a comorbidity of obesity.)\n##\n(\"entity\"<|>SLEEP APNEA<|>EVENT<|>Sleep apnea is a sleep disorder that can be exacerbated by obesity and is often addressed in obesity treatment plans.)\n##\n(\"relationship\"<|>MIGUEL A. RUBIO HERRERA<|>DIABETES<|>Miguel A. Rubio Herrera may provide treatment and management for patients with diabetes as part of obesity care.<|>6)\n##\n(\"relationship\"<|>MIGUEL A. RUBIO HERRERA<|>HYPERTENSION<|>Miguel A. Rubio Herrera may address hypertension in patients undergoing obesity treatment.<|>6)\n##\n(\"relationship\"<|>MIGUEL A. RUBIO HERRERA<|>DYSPLIPIDEMIA<|>Miguel A. Rubio Herrera may manage dyslipidemia in patients with obesity.<|>6)\n##\n(\"relationship\"<|>MIGUEL A. RUBIO HERRERA<|>SLEEP APNEA<|>Miguel A. Rubio Herrera may provide care for patients with sleep apnea related to obesity.<|>6)\n##\n(\"relationship\"<|>CARMEN MORENO LOPERA<|>DIABETES<|>Carmen Moreno Lopera may assist in managing diabetes in primary care settings related to obesity.<|>6)\n##\n(\"relationship\"<|>CARMEN MORENO LOPERA<|>HYPERTENSION<|>Carmen Moreno Lopera may help manage hypertension in patients with obesity in her primary care role.<|>6)\n##\n(\"relationship\"<|>CARMEN MORENO LOPERA<|>DYSPLIPIDEMIA<|>Carmen Moreno Lopera may address dyslipidemia in her primary care practice for obesity patients.<|>6)\n##\n(\"relationship\"<|>CARMEN MORENO LOPERA<|>SLEEP APNEA<|>Carmen Moreno Lopera may provide care for patients with sleep apnea associated with obesity in her primary care role.<|>6)\n<|COMPLETE|>", "input": "MANY entities and relationships were missed in the last extraction. Remember to ONLY emit entities that match any of the previously extracted types. Add them below using the same format:\n", "parameters": {"model": "gpt-4o-mini", "temperature": 0.0, "frequency_penalty": 0.0, "presence_penalty": 0.0, "top_p": 1.0, "max_tokens": 4000, "n": 1}, "history": [{"role": "user", "content": "\n-Goal-\nGiven a text document that is potentially relevant to this activity and a list of entity types, identify all entities of those types from the text and all relationships among the identified entities.\n \n-Steps-\n1. Identify all entities. For each identified entity, extract the following information:\n- entity_name: Name of the entity, capitalized\n- entity_type: One of the following types: [organization,person,geo,event]\n- entity_description: Comprehensive description of the entity's attributes and activities\nFormat each entity as (\"entity\"<|><entity_name><|><entity_type><|><entity_description>)\n \n2. From the entities identified in step 1, identify all pairs of (source_entity, target_entity) that are *clearly related* to each other.\nFor each pair of related entities, extract the following information:\n- source_entity: name of the source entity, as identified in step 1\n- target_entity: name of the target entity, as identified in step 1\n- relationship_description: explanation as to why you think the source entity and the target entity are related to each other\n- relationship_strength: a numeric score indicating strength of the relationship between the source entity and target entity\n Format each relationship as (\"relationship\"<|><source_entity><|><target_entity><|><relationship_description><|><relationship_strength>)\n \n3. Return output in English as a single list of all the entities and relationships identified in steps 1 and 2. Use **##** as the list delimiter.\n \n4. When finished, output <|COMPLETE|>\n \n######################\n-Examples-\n######################\nExample 1:\nEntity_types: ORGANIZATION,PERSON\nText:\nThe Verdantis's Central Institution is scheduled to meet on Monday and Thursday, with the institution planning to release its latest policy decision on Thursday at 1:30 p.m. PDT, followed by a press conference where Central Institution Chair Martin Smith will take questions. Investors expect the Market Strategy Committee to hold its benchmark interest rate steady in a range of 3.5%-3.75%.\n######################\nOutput:\n(\"entity\"<|>CENTRAL INSTITUTION<|>ORGANIZATION<|>The Central Institution is the Federal Reserve of Verdantis, which is setting interest rates on Monday and Thursday)\n##\n(\"entity\"<|>MARTIN SMITH<|>PERSON<|>Martin Smith is the chair of the Central Institution)\n##\n(\"entity\"<|>MARKET STRATEGY COMMITTEE<|>ORGANIZATION<|>The Central Institution committee makes key decisions about interest rates and the growth of Verdantis's money supply)\n##\n(\"relationship\"<|>MARTIN SMITH<|>CENTRAL INSTITUTION<|>Martin Smith is the Chair of the Central Institution and will answer questions at a press conference<|>9)\n<|COMPLETE|>\n\n######################\nExample 2:\nEntity_types: ORGANIZATION\nText:\nTechGlobal's (TG) stock skyrocketed in its opening day on the Global Exchange Thursday. But IPO experts warn that the semiconductor corporation's debut on the public markets isn't indicative of how other newly listed companies may perform.\n\nTechGlobal, a formerly public company, was taken private by Vision Holdings in 2014. The well-established chip designer says it powers 85% of premium smartphones.\n######################\nOutput:\n(\"entity\"<|>TECHGLOBAL<|>ORGANIZATION<|>TechGlobal is a stock now listed on the Global Exchange which powers 85% of premium smartphones)\n##\n(\"entity\"<|>VISION HOLDINGS<|>ORGANIZATION<|>Vision Holdings is a firm that previously owned TechGlobal)\n##\n(\"relationship\"<|>TECHGLOBAL<|>VISION HOLDINGS<|>Vision Holdings formerly owned TechGlobal from 2014 until present<|>5)\n<|COMPLETE|>\n\n######################\nExample 3:\nEntity_types: ORGANIZATION,GEO,PERSON\nText:\nFive Aurelians jailed for 8 years in Firuzabad and widely regarded as hostages are on their way home to Aurelia.\n\nThe swap orchestrated by Quintara was finalized when $8bn of Firuzi funds were transferred to financial institutions in Krohaara, the capital of Quintara.\n\nThe exchange initiated in Firuzabad's capital, Tiruzia, led to the four men and one woman, who are also Firuzi nationals, boarding a chartered flight to Krohaara.\n\nThey were welcomed by senior Aurelian officials and are now on their way to Aurelia's capital, Cashion.\n\nThe Aurelians include 39-year-old businessman Samuel Namara, who has been held in Tiruzia's Alhamia Prison, as well as journalist Durke Bataglani, 59, and environmentalist Meggie Tazbah, 53, who also holds Bratinas nationality.\n######################\nOutput:\n(\"entity\"<|>FIRUZABAD<|>GEO<|>Firuzabad held Aurelians as hostages)\n##\n(\"entity\"<|>AURELIA<|>GEO<|>Country seeking to release hostages)\n##\n(\"entity\"<|>QUINTARA<|>GEO<|>Country that negotiated a swap of money in exchange for hostages)\n##\n##\n(\"entity\"<|>TIRUZIA<|>GEO<|>Capital of Firuzabad where the Aurelians were being held)\n##\n(\"entity\"<|>KROHAARA<|>GEO<|>Capital city in Quintara)\n##\n(\"entity\"<|>CASHION<|>GEO<|>Capital city in Aurelia)\n##\n(\"entity\"<|>SAMUEL NAMARA<|>PERSON<|>Aurelian who spent time in Tiruzia's Alhamia Prison)\n##\n(\"entity\"<|>ALHAMIA PRISON<|>GEO<|>Prison in Tiruzia)\n##\n(\"entity\"<|>DURKE BATAGLANI<|>PERSON<|>Aurelian journalist who was held hostage)\n##\n(\"entity\"<|>MEGGIE TAZBAH<|>PERSON<|>Bratinas national and environmentalist who was held hostage)\n##\n(\"relationship\"<|>FIRUZABAD<|>AURELIA<|>Firuzabad negotiated a hostage exchange with Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>AURELIA<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>FIRUZABAD<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>ALHAMIA PRISON<|>Samuel Namara was a prisoner at Alhamia prison<|>8)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>MEGGIE TAZBAH<|>Samuel Namara and Meggie Tazbah were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>DURKE BATAGLANI<|>Samuel Namara and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>DURKE BATAGLANI<|>Meggie Tazbah and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>FIRUZABAD<|>Samuel Namara was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>FIRUZABAD<|>Meggie Tazbah was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>DURKE BATAGLANI<|>FIRUZABAD<|>Durke Bataglani was a hostage in Firuzabad<|>2)\n<|COMPLETE|>\n\n######################\n-Real Data-\n######################\nEntity_types: organization,person,geo,event\nText: 8;\n  7.   Samaha FF, Iqbal N, Seshadri P, Chicano KL, Daily                87:621-6.\n       DA, McGrory J, et al. A low-carbohydrate as com-            20.  Trowman R, Dumville JC, Hahn S, Torgerson DJ. A\n       pared with a low-fat diet in severe obesity. N Engl              systematic review of calcium supplementation on\n       J Med 2003; 348: 2074-81.                                        body weight. Br J Nutr 2006; 95:1033-8.\n  8.   Gibson AA, Seimon R V., Lee CMY, Ayre J, Franklin           21.  Salas-Salvadó J, Farrés X, Luque X, Narejos S, Bo-\n       J, Markovic TP, et al. Do ketogenic diets really su-             rrell M, Basora J, et al.       Effect of two doses of a\n       ppress appetite? A systematic review and me-                     mixture of soluble fibres on body weight and me-\n       ta-analysis. Obes Rev 2015; 16:64-76.                            tabolic variables in overweight or obese patients: a\n  9.   Schwingshackl       L,  Hoffmann       G.   Comparison  of       randomised trial. Br J Nutr. 2008; 99:1380-7.\n       effects of long-term low-fat vs high-fat diets on           22.  Eiler WJ, Džemidžić M, Case KR, Soeurt CM, Arm-\n       blood lipid levels in overweight orobese patients: a             strong CL, Mattes RD, et al. The apéritif effect: Al-\n       systematic review and meta-analysis. J Acad Nutr                 cohol’s effects on the brain’s response to food\n       Diet 2013; 113:1640-61.                                          aromas in women. Obesity (Silver Spring). 2015;\n10.    Ludwig DS. The glycemic index: physiological me-                 23:1386-93.\n       chanisms relating to obesity, diabetes, and cardio-         23.  Horikawa C, Kodama S, Yachi Y, Heianza Y, Hira-\n       vascular disease. JAMA 2002; 287: 2414-2423.                     sawa R, Ibe Y, et al. Skipping breakfast and preva-\n---\n                                                                       Tema 7.    Tratamiento dietético de la obesidad       131\n\n\n\n     lence of overweight and obesity in Asian and Paci-           25.   Lecube A, Monereo S, Rubio MÁ, Martínez-de-Ica-\n     fic  regions:    a   meta-analysis.      Prev   Med.  2011;        ya P, Martí A, Salvador J, et al. Prevención, diag-\n     53:260-7.                                                          nóstico y tratamiento de la obesidad. Posiciona-\n24.  Schoenfeld BJ, Aragon AA, Krieger JW. Effects of                   miento de la Sociedad Española para el Estudio de\n     meal frequency on weight loss and body composi-                    la Obesidad de 2016. Endocrinol Nutr. 2016 Aug\n     tion: a meta-analysis. Nutr Rev. 2015; 73:69-82.                   16. pii: S1575-0922(16)30109-7.\n---\nNO_CONTENT_HERE\n---\nTema 8.\nTratamiento farmacológico de la obesidad\nMiguel A. Rubio Herrera\nServicio de Endocrinología y Nutrición. Hospital Clínico Universitario San Carlos. Madrid\nCarmen Moreno Lopera\nAtención Primaria. Centro de Salud Lucero. Madrid\n\n\n\nDietoterapia, nutrición clínica y metabolismo. Tercera edición. Copyright 2017 de los autores, SEEN y Grupo Aula Médica.\nTodos los derechos reservados. Páginas 133-141.\n\n\n\n   1.  Introducción\n   2.  Fármacos comercializados no disponibles en Europa\n   3.  Fármacos comercializados en Europa\n   4.  Futuro de los tratamientos para la obesidad\n   5.  Bibliografía\n\n\n\n1.   Introducción                                                            del tratamiento farmacológico para la obesidad se esta-\n   Las guías de práctica clínica indican que una pérdida                     blecen para los sujetos con un índice de masa corporal\n                                                                             (IMC) ≥ 30 kg/m2 o ≥ 27 kg/m2 en presencia de comor-\ndel 5 al 10% del peso corporal que se alcanza con los                        bilidades mayores (diabetes, hipertensión, dislipemia,\ncambios en el estilo de vida (alimentación hipocalórica                      apneas del sueño, etc.)5, siempre asociadas a medidas\ny ejercicio) es suficiente para reducir el impacto de las\ncomorbilidades asociadas a la obesidad1. Ese objetivo                        dietéticas y cambios en el estilo de vida. De la misma\nparece asumible y fácilmente factible a corto plazo para                     manera, si tras 12-16 semanas de tratamiento activo el\nla mayoría de los\n######################\nOutput:"}, {"role": "assistant", "content": "(\"entity\"<|>HOSPITAL CLÍNICO UNIVERSITARIO SAN CARLOS<|>ORGANIZATION<|>Hospital Clínico Universitario San Carlos is a medical institution in Madrid specializing in endocrinology and nutrition.)\n##\n(\"entity\"<|>CENTRO DE SALUD LUCERO<|>ORGANIZATION<|>Centro de Salud Lucero is a primary care health center located in Madrid.)\n##\n(\"entity\"<|>MIGUEL A. RUBIO HERRERA<|>PERSON<|>Miguel A. Rubio Herrera is a medical professional associated with the Hospital Clínico Universitario San Carlos, specializing in obesity treatment.)\n##\n(\"entity\"<|>CARMEN MORENO LOPERA<|>PERSON<|>Carmen Moreno Lopera is a healthcare professional working at the Centro de Salud Lucero in Madrid, focusing on primary care.)\n##\n(\"entity\"<|>OBESITY<|>EVENT<|>Obesity is a medical condition characterized by excessive body fat, which can lead to various health issues and requires treatment.)\n##\n(\"relationship\"<|>MIGUEL A. RUBIO HERRERA<|>HOSPITAL CLÍNICO UNIVERSITARIO SAN CARLOS<|>Miguel A. Rubio Herrera is affiliated with the Hospital Clínico Universitario San Carlos, where he works in endocrinology and nutrition.<|>8)\n##\n(\"relationship\"<|>CARMEN MORENO LOPERA<|>CENTRO DE SALUD LUCERO<|>Carmen Moreno Lopera is associated with the Centro de Salud Lucero, providing primary healthcare services.<|>8)\n##\n(\"relationship\"<|>HOSPITAL CLÍNICO UNIVERSITARIO SAN CARLOS<|>OBESITY<|>The Hospital Clínico Universitario San Carlos provides treatment for obesity through its endocrinology department.<|>7)\n##\n(\"relationship\"<|>CENTRO DE SALUD LUCERO<|>OBESITY<|>Centro de Salud Lucero offers primary care services that include management and treatment of obesity-related conditions.<|>7)\n<|COMPLETE|>"}]}